Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial
Authors' conclusion
Tirzepatide treatment significantly reduced the 10-year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.
Study context
- Population
- SURMOUNT-1 participants with obesity or overweight
- Comparison
- Tirzepatide 5, 10 or 15 mg vs placebo
- Primary endpoint
- Mean change in 10-year predicted risk of T2D (Cardiometabolic Disease Staging risk engine)
- Follow-up
- Baseline to weeks 24 and 72
Methodological detailssubgroup analyses by baseline glycaemic status and BMI
- Subgroup analyses by baseline glycaemic status and BMI
Primary result
As reported in the abstract
Mean absolute T2D predicted risk score reduction · week 72
5 mg
12.4%
mean
10 mg
14.4%
mean
15 mg
14.7%
mean
Placebo
0.7%
mean
Further findings
Mean baseline T2D predicted risk score
- Did not differ between tirzepatide and placebo groups (range)
- 22.9%-24.3%
Median relative predicted risk reduction with tirzepatide · week 72
- Range across tirzepatide doses
- 60.3% to 69.0%
Risk reduction by prediabetes status · week 72
- Mean risk score reduction, with prediabetes (range)
- 16.0%-20.3%
- Mean risk score reduction, without prediabetes (range)
- 10.1%-11.3%
- Significantly greater with tirzepatide vs placebo in participants with and without prediabetes
Risk reduction by BMI subgroup
- Mean reductions significantly greater with tirzepatide vs placebo across BMI subgroups
Original publication
Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT ‐1 trial. Diabetes Obes Metab. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →